Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Exploring Therapeutic Options Over the Continuum of Metastatic Breast Cancer

Release Date: April 1, 2009| Expiration Date: April 1, 2010
0.75 AMA PRA Category 1 Credit(s)™| Mar 5, 2009, Miami, FL

Lecture Overview

The Exploring Therapeutic Options Over the Continuum of Metastatic Breast Cancer symposium is designed to update physicians on the latest information regarding the development of the next generation of cytotoxic agents and how to integrate this information into their everyday practices. The current status of taxane-based chemotherapy in the treatment of metastatic breast cancer will be discussed. This symposium will also evaluate current options for the treatment of advanced disease that has become refractory to standard therapies, including the latest data on newer classes of microtubule-targeting drugs, such as epothilones and halichondrin B analogues, and the rationale behind the use of these agents based on the current knowledge of resistance mechanisms. Concepts regarding the optimization of treatment using established and newer cytotoxic agents in defined clinical scenarios and situations where controversies exist will be illustrated using cases and panel discussion.

This educational program is directed toward medical oncologists, surgeons, and radiation oncologists interested in the treatment of breast cancer. Physician assistants, research nurses, and fellows interested in the treatment of patients with breast cancer are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Assess the current status of both traditional and novel microtubule inhibitors with respect to efficacy, safety, and schedule optimization in the treatment of breast cancer
  • Discuss the rationale for and data on the incorporation of novel tubulin-binding agents or targeted agents into therapeutic regimens for metastatic breast cancer
  • Apply decision-making principles to specific clinical scenarios in order to optimize the benefit/risk profile of chemotherapeutic regimens for advanced breast cancer based on available data and clinical guidelines

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Complete the test(s) and evaluation by April 1, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Exploring Therapeutic Options Over the Continuum of Metastatic Breast Cancer symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Hope S. Rugo, MD
Research Funding – Abbott Laboratories, Abraxis Bioscience, LLC, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc.; Speaker’s Bureau – AstraZeneca, Genomic Health, Inc.

Mark Pegram, MD
Paid Consultant/Advisory Board – Genentech, Inc.; GlaxoSmithKline; sanofi-aventis U.S.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users

If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users

Compatible Web browsers include:

Additional software requirements include:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2009 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, Exploring Therapeutic Options Over the Continuum of Metastatic Breast Cancer
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Bristol-Myers Squibb